Drugs / Recombinant human luteinizing hormone (rhLH)
Recombinant human luteinizing hormone (rhLH)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01075815 | Nov 2008 → Oct 2010 | infertility disorder, ovarian disorder | Merck KGaA, Darmstadt, Germany | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human luteinizing hormone (rhLH) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01075815 ↗ |
| Modality | Protein / enzyme biologic | “recombinant luteinizing hormone (r-LH) supplementation” NCT01075815 ↗ |
| Route | Subcutaneous | “injection 150 IU subcutaneously daily” NCT01075815 ↗ |